Differential regulation of TGF-β 2-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma

Neuro-Oncology

Volumn 17, Issue 2, 2015, Pages 254-265

  Seystahl, Katharina ^a   Tritschler, Isabel ^a   Szabo, Emese ^a   Tabatabai, Ghazaleh ^a   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

angiogenesis; glioblastoma; TGF 2; VEGF

Indexed keywords

SMAD PROTEIN; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; VASCULOTROPIN; MESSENGER RNA; PROTEIN SERINE THREONINE KINASE; RECEPTOR REGULATED SMAD PROTEIN; SMAD1 PROTEIN, HUMAN; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; SMAD5 PROTEIN, HUMAN; SMAD8 PROTEIN, HUMAN; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; GLIOBLASTOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; BRAIN TUMOR; GENE EXPRESSION REGULATION; METABOLISM; SECRETION (PROCESS); TUMOR CELL CULTURE; TUMOR CELL LINE;

BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HUMANS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD PROTEINS, RECEPTOR-REGULATED; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84924980270     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou218     Document Type: Article

References (42)

1. Bruna A, Darken RS, Rojo F, et al. High TGFb-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007;11(2):147-160.
2. Ständer M, Naumann U, Dumitrescu L, et al. Decorin gene transfer-mediated suppression of TGF-b synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther. 1998; 5(9):1187-1194.
3. Friese MA, Wischhusen J, Wick W, et al. RNA interference targeting transforming growth factor-b enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 2004;64(20):7596-7603.
4. Uhl M, Aulwurm S, Wischhusen J, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004;64(21):7954-7961.
5. Tran TT, Uhl M, Ma JY, et al. Inhibiting TGF-b signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol. 2007;9(3):259-270.
6. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-b2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011;13(1):132-142.
7. Carpentier A, Brandes A, Kesari S, et al. Safety interim data from a three-arm phase II study evaluating safety and pharmakokinetics of the oral transforming growth factor-beta (TGF-b) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression [abstract 2061]. J Clin Oncol 2013;31:(suppl).
8. Groppe J, Hinck CS, Samavarchi-Tehrani P, et al. Cooperative assembly of TGF-b superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell. 2008;29(2):157-168.
9. Kubiczkova L, Sedlarikova L, Hajek R, et al. TGF-b-an excellent servant but a bad master. J Transl Med. 2012;10:183.
10. Zhang M, Kleber S, Rohrich M, et al. Blockade of TGF-b signaling by the TGFbR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res. 2011;71(23):7155-7167.
11. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFb/ALK5 signaling. Mol Cell. 2003;12(4):817-828.
12. Boström K, Zebboudj AF, Yao Y, et al. Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-b1 activity in endothelial cells. J Biol Chem. 2004;279(51): 52904-52913.
13. Liu Z, Kobayashi K, van Dinther M, et al. VEGFand inhibitors of TGFb type-I receptor kinase synergistically promote blood-vessel formation by inducing alpha5-integrin expression. J Cell Sci. 2009;122(Pt 18):3294-3302.
14. Koochekpour S, Merzak A, Pilkington GJ. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-b isoforms in human glioma cells in vitro. Cancer Lett. 1996; 102(1-2):209-215.
15. Tabatabai G, Herrmann C, von Kurthy G, et al. VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. Brain. 2008; 131(Pt 10):2579-2595.
16. Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, et al. SB-431542, a small molecule transforming growth factor-b-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther. 2004;3(6):737-745.
17. Weller M, Rieger J, Grimmel C, et al. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer. 1998;79(6):640-644.
18. Rieger J, Lemke D, Maurer G, et al. Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL-XL. J Neurochem. 2008;106(6):2436-2448.
19. Weiler M, Pfenning PN, Thiepold AL, et al. Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment. Oncogene. 2013;32(9):1099-1109.
20. Weksler BB, Subileau EA, Perriere N, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005;19(13):1872-1874.
21. Zawel L, Dai JL, Buckhaults P, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell. 1998;1(4): 611-617.
22. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604-4613.
23. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7): 1168-1174.
24. Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31(26): 3212-3218.
25. Stupp R, Hegi M, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study [abstract LBA2009]. J Clin Oncol 2013;31:(suppl).
26. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
27. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740-745.
28. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
29. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
30. Reardon DA, Turner S, Peters KB, et al. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw. 2011;9(4):414-427.
31. Wakefield LM, Hill CS. Beyond TGFb: roles of other TGFb superfamily members in cancer. Nat Rev Cancer. 2013;13(5): 328-341.
32. Wrighton KH, Lin X, Yu PB, et al. Transforming Growth Factor b Can Stimulate Smad1 Phosphorylation Independently of Bone Morphogenic Protein Receptors. J Biol Chem. 2009;284(15): 9755-9763.
33. Fontana A, Hengartner H, de Tribolet N, et al. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol. 1984;132(4):1837-1844.
34. Leitlein J, Aulwurm S, Waltereit R, et al. Processing of immunosuppressive pro-TGF-b1, 2 by human glioblastoma cells involves cytoplasmic and secreted furin-like proteases. J Immunol. 2001;166(12):7238-7243.
35. Wei J, Wu A, Kong LY, et al. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One. 2011;6(1):e16195.
36. Chattopadhyay N, T-Felt Hansen J, Godbole MM, et al. Transforming growth factor beta receptor family ligands inhibit hepatocyte growth factor synthesis and secretion from astrocytoma cells. Brain Res Mol Brain Res. 2004;121(1-2): 146-150.
37. Pistollato F, Rampazzo E, Abbadi S, et al. Molecular mechanisms of HIF-1a modulation induced by oxygen tension and BMP2 in glioblastoma derived cells. PLoS One. 2009;4(7):e6206.
38. Shao ES, Lin L, Yao Y, et al. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood. 2009;114(10): 2197-2206.
39. Eichhorn PJ, Rodon L, Gonzalez-Junca A, et al. USP15 stabilizes TGF-b receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma. Nat Med. 2012; 18(3):429-435.
40. Pagès G, Pouyssegur J. Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc Res. 2005;65(3):564-573.
41. Sanchez-Elsner T, Botella LM, Velasco B, et al. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem. 2001;276(42):38527-38535.
42. Roth P, Silginer M, Goodman SL, et al. Integrin control of the transforming growth factor-b pathway in glioblastoma. Brain. 2013;136(Pt 2):564-576.